Privia Health Reports Officer/Director Changes, Comp Arrangements
Ticker: PRVA · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1759655
| Field | Detail |
|---|---|
| Company | Privia Health Group, Inc. (PRVA) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Privia Health just reported executive changes and new pay deals, watch for strategic shifts.**
AI Summary
Privia Health Group, Inc. filed an 8-K on January 29, 2024, reporting an event on January 25, 2024, related to changes in directors or officers and their compensation arrangements. This filing indicates potential shifts in leadership or executive incentives, which could impact the company's strategic direction and financial performance. Investors should pay attention to the specifics of these changes as they can signal confidence (or lack thereof) in the company's future and influence stock valuation.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's strategy, operational efficiency, and ultimately, its stock performance. Investors need to understand who is leading the company and how they are incentivized.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty, but also opportunities for new strategic direction, making the risk level moderate.
Analyst Insight
Investors should monitor Privia Health Group, Inc.'s future filings and press releases for specific details on the executive changes and compensation arrangements mentioned in this 8-K, as these specifics will clarify the potential impact on the company's strategy and financial outlook.
Key Numbers
- 2024-01-25 — Date of Earliest Event Reported (Indicates when the reported changes in officers/directors and compensation arrangements occurred.)
- 001-40365 — Commission File Number (Unique identifier for Privia Health Group, Inc. with the SEC.)
Key Players & Entities
- Privia Health Group, Inc. (company) — the registrant filing the 8-K
- January 25, 2024 (date) — date of the earliest event reported
- January 29, 2024 (date) — date the 8-K was filed
- 001-40365 (other) — Commission File No.
- PRVA (other) — Trading Symbol for Common Stock
- $0.01 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Privia Health Group, Inc. will provide more detailed information regarding the specific officers or directors affected and their new compensatory arrangements in subsequent filings or disclosures. (Privia Health Group, Inc.) — medium confidence, target: 2024-03-31
FAQ
What specific items were reported in this 8-K filing by Privia Health Group, Inc.?
The 8-K filing by Privia Health Group, Inc. reported information under 'ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'ITEM INFORMATION: Regulation FD Disclosure', and 'ITEM INFORMATION: Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 25, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 25, 2024'.
What is the trading symbol and par value of Privia Health Group, Inc.'s Common Stock?
The trading symbol for Privia Health Group, Inc.'s Common Stock is PRVA, and its par value is $0.01 per share, as indicated under 'Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, $0.01 par value per share Trading Symbol(s) PRVA'.
Where is Privia Health Group, Inc.'s principal executive office located?
Privia Health Group, Inc.'s principal executive office is located at 950 N. Glebe Rd., Suite 700, Arlington, Virginia 22203, according to the filing's 'Address of Principal Executive Offices'.
What is the purpose of an 8-K filing for investors?
An 8-K filing, like this one from Privia Health Group, Inc., is used to announce major events that shareholders should know about, such as changes in leadership or compensation, which can significantly impact the company's future performance and stock value.
Filing Stats: 1,084 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2024-01-29 08:52:42
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share PRVA The Nasdaq Glo
Filing Documents
- prva-20240125.htm (8-K) — 32KB
- ex-101transitionletteragre.htm (EX-10.1) — 95KB
- ex-991neotransition.htm (EX-99.1) — 46KB
- privialogo.jpg (GRAPHIC) — 8KB
- 0001759655-24-000011.txt ( ) — 338KB
- prva-20240125.xsd (EX-101.SCH) — 2KB
- prva-20240125_lab.xml (EX-101.LAB) — 24KB
- prva-20240125_pre.xml (EX-101.PRE) — 13KB
- prva-20240125_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 29, 2024, the Company issued a press release announcing the departure of Mr. Bartrum and appointment of Mr. Fargis as Executive Vice President & General Counsel. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit: Exhibit No. Description 10.1 Transition Letter Agreement, dated as of January 25, 2024, between the Company and Thomas Bartrum 99.1 Privia Health Group, Inc. Press Release Dated January 29, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRIVIA HEALTH GROUP, INC. Date: January 29, 2024 By: /s/ David Mountcastle Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer